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Abstract
Published data indicate that formulation of pDNA with cationic lipids could greatly enhance the
response to a pDNA vaccine in larger mammals. The present work tested the influence of several
pDNA:cationic lipid formulations on rabies neutralizing titers. Plasmid expressing Rabies G protein
(CVS strain) was evaluated in vivo for ability to elicit neutralizing titers. pDNA:DMRIE-DOPE
formulated at two DNA:cationic lipid molar ratios was compared in mice to a Vaxfectin™-pDNA
formulation. Mouse data indicate that Vaxfectin™ is more effective than DMRIE-DOPE in eliciting
neutralizing titers. In addition, the ratio of pDNA to DMRIE-DOPE can also affect neutralizing
titers. Our data show that sustained neutralizing titers (120 days) can be obtained after a single
administration of DMRIE-DOPE-formulated pDNA in rabbits.
Introduction
Each year rabies kills more than 50,000 people and mil-
lions of animals worldwide [1]. Although vaccination of
dogs, elimination of strays and control of wild animals
have been effective in preventing most cases of human
rabies in North America and Western Europe, the same
approaches have been difficult to implement in parts of
the developing world because of cultural, economic and
political reasons. Therefore, a pressing need for safe, effec-
tive and affordable human rabies vaccines still exists in
some developing countries. Plasmid DNA (pDNA) vac-
cines could fill this gap due to their demonstrated safety,
speed and ease of development, and their inherent stabil-
ity allowing for long-term stockpiling and simplified dis-
tribution.
Rabies vaccines of nerve tissue origin have been available
for post-exposure use in humans since the end of the 19th
century. These vaccines are inexpensive but of relatively
low potency requiring a difficult vaccination schedule of
14 to 21 inoculations with two booster doses for post-
exposure treatments. In addition, serious side effects are
frequently associated with these vaccines, which limit
their suitability for pre-exposure prophylaxis. Many devel-
oping countries still depend on nerve tissue-derived vac-
cines. Safe and highly efficacious rabies vaccines produced
in cell culture have been available for almost 30 years in
affluent countries. Three rabies vaccines are currently
available in the United States for human use: human dip-
loid cell vaccine (HDCV); rabies vaccine adsorbed (RVA);
and purified chick embryo cell culture vaccine (PCECV).
All three vaccines can be used in both pre- and post-expo-
sure applications. In spite of the efficacy and safety profile
of cell culture vaccines, manufacturing, storage and distri-
bution costs make them prohibitive for widespread use in
many poorer countries. Other rabies vaccine approaches
under evaluation include the use of vaccinia virus [2-4]
and pDNA [5,6] to deliver rabies antigens.
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strated in several animal models including mice [5], dogs
[7], cats [8], horses [9] and non-human primates [6,10].
Interestingly, a single administration of rabies pDNA vac-
cine in mice was as effective as five doses of a cell culture
derived vaccine [11]. Several routes of administration
have been tested including intramuscular [5,9], intrader-
moplantar [12] and intradermal [5,7]. pDNA has also
been delivered using the Biolistic® system [13] as well as
by needle injection. Rabies pDNA vaccines have been
delivered in PBS [9,11], Adju-Phos® (aluminum phos-
phate) [9], monophosphoryl lipid A [5] as well as cationic
lipid formulations [9]. The choice of formulation can be
critical for the effectiveness of the vaccine, as shown by
Fischer and co-workers [9] who demonstrated that a cati-
onic lipid-formulated rabies pDNA vaccine was more
effective in eliciting a humoral response than aluminum
phosphate or PBS formulation. The proof of concept of
pDNA rabies vaccines in animal models suggests that
development of an effective pDNA vaccine for human
immunization should be achievable.
Protection against rabies infection depends primarily on
humoral immunity [14]. Intramuscular injection of
pDNA in PBS has been shown to elicit potent cellular but
relatively low antibody responses [15,16]. Therefore, the
use of formulations that drive robust antibody responses
would be expected to improve the performance of a
pDNA rabies vaccine beyond that achievable with pDNA
in PBS. Complexation of immunogen-encoding pDNA
with cationic lipid systems, such as DMRIE-DOPE and
Vaxfectin™ [15] offers a potential enhancement to the rel-
atively weak humoral response elicited by pDNA in PBS.
For instance, Hartikka and co-workers [17] showed a 20-
fold increase in antibody titers against influenza nucleo-
protein when formulating pDNA with Vaxfectin™ com-
pared to titers obtained with pDNA in PBS. Recently,
Hermanson and co-workers [18] demonstrated the suc-
cessful protection of rabbits against a lethal dose of aero-
solized anthrax spores after immunization with a
pDNA:DMRIE-DOPE vaccine. Fischer and collaborators
[9] were able to elicit protective titers in horses after a sin-
gle injection of pDNA:DMRIE-DOPE. In addition, Fischer
demonstrated that titers obtained after administration of
rabies pDNA:cationic lipid were higher than those
obtained after administration of pDNA:Adju-Phos® and
no detectable antibodies were obtained after one injection
of pDNA in PBS.
Previous published work [9,19] indicates that pDNA:cati-
onic lipid formulations could prove successful in raising
protective rabies antibody titers in larger mammals. Par-
ticularly, Fischer's data on horse pDNA vaccinations [9]
indicate that DMRIE-DOPE could be used as a component
of such a vaccine; moreover, pDNA:DMRIE-DOPE vac-
cines are currently being evaluated in human trials [20].
However, there are no published data on the effect of dif-
ferent cationic lipid formulations on rabies titers. Our
results suggest that the cationic lipid Vaxfectin™ appears to
be a better candidate than DMRIE-DOPE for formulating
a pDNA rabies vaccine. In addition, higher titers were
observed at low vaccine doses in mice when DMRIE-
DOPE was used at a 4:1 molar ratio (pDNA:cationic lipid)
as opposed to the 2.5:1 ratio reported previously [9]. Vac-
cination of rabbits with pDNA:DMRIE-DOPE resulted in
high levels of neutralizing antibodies that persisted for a
minimum of 195 days; moreover, data from rabbit studies
indicate that protective titers can be obtained with low
doses (10 µg) of pDNA:cationic lipid. The fact that protec-
tive antibodies were observed 21 days after pDNA admin-
istration for all the cationic lipid formulations tested
supports the use of rabies pDNA vaccine for post-exposure
therapy. In summary, our data suggest that the choice of
cationic lipid system as well as the pDNA:cationic lipid
ratios can offer significant enhancement to the humoral
response to rabies pDNA vaccines.
Materials and methods
pDNA and formulations
DNA coding for wild type rabies glycoprotein G (G pro-
tein; CVS strain) was subcloned from plasmid pKB3-JE13
[22] (Clone #40280; ATCC, Manassas, VA) into expres-
sion plasmid VR1051 using the Eco RI restriction site. The
resulting plasmid was designated VR7203. VR1051 is sim-
ilar to the VR1055 construct previously described [22],
except for the multiple cloning site. G protein expression
was tested in vitro by transfecting VM92 (murine
melanoma cells; Vical Inc., San Diego, CA) cells with
VR7203 using lipofection. The presence of G protein in
transfection supernatants was confirmed by Western blot
analysis using an anti-rabies monoclonal antibody (QED
Bioscience, cat# 20501; San Diego, CA)(data not shown).
DMRIE-DOPE consists of a 1:1 molar ratio of DMRIE: (±)-
N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecy-
loxy)-1-propanaminium bromide and DOPE: 1,2-Diole-
oyl-sn-glycero-3-phosphoethanolamine [23]. The
DMRIE-DOPE lipid mixture was diluted to 1.5 mM with
sterile water and added to an equal volume of pDNA (2
mg/mL in 2× PBS) and vortexed briefly. The final DNA:
cationic lipid molar ratio of formulation was either 4:1 or
2.5:1, depending on the test group.
Vaxfectin™ consists of an equimolar mixture of VC1052
((±)-N- (3-aminopropyl)-N,N-dimethyl-2, 3-bis (myris-
toleyloxy)-1-propanaminium bromide) and DPyPE
(Diphytanoylphosphatidyl-ethanolamine). Preparation
of Vaxfectin™ and its formulations is described in detail by
Hartikka and co-workers [17]. Briefly, the molar ratio of
pDNA:cationic lipid of Vaxfectin™ formulation is 4:1.Page 2 of 6
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(pH 7.2) at double the final concentration. Vaxfectin™ is
suspended from a dry film state in 0.9% NaCl at double
the final concentration.
Animal procedures
All animal procedures were approved by Vical's IACUC
and complied with the standards set forth in the Guide for
the Care and Use of Laboratory Animals (U.S. Department of
Health Services, NIH; Bethesda, MD) and the USDA's
(Washington, DC) Animal Welfare Act and Animal Welfare
Regulations.
Groups of ten, six- to eight-week old female BALB/c mice
(Jackson Labs; Bar Harbor ME) were vaccinated by bilat-
eral intramuscular injection of cationic lipid-formulated
pDNA (either 2 or 5 µg; 50 µL per leg) into the quadriceps
muscle group. Mice were bled at days 1 and 21 by orbital
sinus puncture. The final bleed was done by cardiac punc-
ture 48 days after pDNA administration. Serum samples
were tested for neutralizing antibodies by the Rapid Fluo-
rescence Focus Inhibition Test (RFFIT).
Groups of three New Zealand white rabbits (Harlan
Sprague-Dawley; Oxford, MI), received plasmid VR7203
formulated with DMRIE-DOPE (4:1 DNA:cationic lipid
molar ratio) in PBS in a total volume of 0.5 mL per intra-
muscular injection (rectus femoris bilateral injection);
pDNA doses ranged from 10 µg to 1 mg, depending on
the experiment. Positive control groups received a single
dose of IMRAB® 3 (Merial, Lyon, France), a commercially
available rabies veterinary vaccine. Animals were bled at
regular intervals until the end of the study. Serum was
tested for rabies neutralizing titers by RFFIT.
Neutralizing titer determination and interpretation
Rabies neutralizing titers were determined by Rapid Fluo-
rescence Focus Inhibition Test (RFFIT) at Atlanta Health
Associates (Cumming, GA) using rabies CVS and standard
assay techniques. Briefly, dilutions of heat-inactivated
serum are incubated with a fixed amount of rabies virus
(CVS strain) for 60–90 min at 37°C. Residual virus infec-
tivity is then determined by inoculating cell cultures with
the virus. Foci of virus infected cells are stained and
detected by fluorescence and counted. According to the
World Health Organization's Expert Rabies Committee
[1] and the United States Centers for Disease Control and
Prevention an antibody level of > 0.5 International Units
(IU)/mL of serum indicates a positive protective antibody
response to vaccination.
Statistical analysis
Statistical analyses were conducted with SAS computer
software (SAS Institute, Cary, NC). A general linear model
(GLM) was performed with formulation, dose as the class
variables and experimental data as the dependent varia-
ble. The interaction term of formulation dose was exam-
ined in the GLM model. Tukey method and contrast
statement were used for the group-wise comparisons. Sta-
tistical significance was determined at α = 0.05 level with
2-sided test.
Results
Vaccination of rabbits with rabies G protein pDNA results 
in sustained high protective neutralizing titers
Groups of three rabbits were vaccinated with either the
DMRIE-DOPE-formulated VR7203 plasmid (4:1
DNA:cationic lipid ratio) or the conventional rabies vac-
cine, IMRAB® 3. Rabbits in the pDNA group were vacci-
nated on Days 1, 28 and 56 with 1 mg (bilateral injection;
500 µg/500 µL per leg) of DMRIE-DOPE-formulated
pDNA and were bled at regular intervals for serum collec-
tion. Animals in the IMRAB® 3 group received a single
administration of the vaccine (1 mL) and were bled on the
same schedule as the pDNA group. Serum from all ani-
mals had titers (Figure 1) higher than the 0.5 IU/mL
threshold by day 21. The serum of rabbits vaccinated with
pDNA reached mean titers of about 100 IU/mL by day 41.
Titers in the pDNA group remained high for the duration
of the study (195 Days) dropping to about 50 IU/mL at
the conclusion of the study. Animals in the control group
Sustained High Protective Titers after pDNA vaccinationFigure 1
Sustained High Protective Titers after pDNA vacci-
nation. Two groups of three rabbits were vaccinated with 
either 1 mg of rabies G protein pDNA VR7203 (Days 1, 28 
and 56) (∆) or with a single administration of IMRAB® 3 (●) 
as described in Materials and Methods. pDNA:cationic lipid 
molar ratio was kept at 4:1. Data points represent individual 
animal titers. Lines connect mean titer values for each group 
at each time point. Protective titer threshold (0.5 IU/mL) is 
indicated with a horizontal line. Vaccination days are indi-
cated with downward arrows.Page 3 of 6
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bleed.
Single administration of rabies G protein pDNA results in 
high protective titers in rabbits
In order to evaluate the immunological response to a sin-
gle pDNA administration, groups of three rabbits were
vaccinated by a single intramuscular injection of either
300 µg or 10 µg of rabies G protein-expressing pDNA for-
mulated with DMRIE-DOPE (4:1 DNA:cationic lipid
ratio). A control group was injected with a commercial
rabies veterinary vaccine, IMRAB® 3. Animals were bled at
regular intervals and the rabies neutralization titers were
obtained by RFFIT assay (Figure 2). All three groups had
protective neutralizing titers (i.e., >0.5 IU /mL) 21 days
after vaccination; high neutralizing titers were maintained
for the duration of the study (120 days). Titers at day 21
were about an order of magnitude higher in the 300 µg
pDNA dose group compared to the 10 µg dose group. Vac-
cination with 300 µg of DMRIE:DOPE-formulated pDNA
resulted in neutralizing titers that were not statistically dif-
ferent from those obtained with the conventional rabies
vaccine. Vaccination with the 10 µg pDNA dose resulted
in protective titers about half a log lower than those
obtained with the 300 µg pDNA dose at day 120 but still
almost two orders of magnitude higher than the protec-
tive threshold (0.5 IU /mL) and not statistically different
from titers obtained using the conventional vaccine.
Vaxfectin™-formulated rabies G protein pDNA induces 
higher neutralizing titers than DMRIE-DOPE-formulated 
pDNA after single administration in mice
The differential effect of DMRIE-DOPE and Vaxfectin™
formulations on rabies neutralizing titers was explored by
vaccinating mice with a single administration of cationic
lipid-formulated pDNA. Two pDNA doses were used (2
µg and 5 µg); DMRIE-DOPE was formulated at a molar
ratio (pDNA:cationic lipid) of either 2.5:1 or 4:1; Vaxfec-
tin™ was formulated at a molar ratio of 4:1 (pDNA:cati-
onic lipid). Neutralizing titers 48 days after vaccinating
mice with Vaxfectin™-formulated VR7203 were statisti-
cally superior (p = 0.004) to those obtained from admin-
istration of pDNA:DMRIE-DOPE at either dose (Figure 3).
In addition, at the 2 µg pDNA dose, titers obtained after
administration of pDNA:DMRIE-DOPE at 4:1 ratio
(DNA:cationic lipid) were marginally superior to the titers
from administration at the 2.5:1 ratio; titers from the 4:1
and 2.5:1 ratios were statistically indistinguishable from
each other at the 5 µg pDNA dose. Serum of all animals in
the Vaxfectin™ group at the 2 µg dose showed protective
neutralizing titers while up to 20% of the mice in the
DMRIE-DOPE groups did not respond to the vaccination.
Discussion
The value of cationic lipid formulations in enhancing
humoral responses to pDNA vaccines is well documented
[9,16,19]. Specifically, efficacy of a pDNA:DMRIE-DOPE
rabies vaccine (2.5:1 pDNA:cationic lipid molar ratio)
was convincingly demonstrated by Fischer and co-workers
using a horse model. Development of a pDNA rabies vac-
cine for human use requires evaluation of improved for-
mulations including alternative cationic lipid systems
such as Vaxfectin™ and the determination of optimal
pDNA:cationic lipid ratios. Our data provide some insight
into possible formulation improvements using two differ-
ent cationic lipid systems. We also provide data compar-
ing the immunogenicity of rabies pDNA to a
commercially available inactivated virus vaccine.
Neutralizing titers obtained after vaccination of mice with
either 2 or 5 µg of cationic lipid-formulated pDNA indi-
cate that Vaxfectin™ can improve the immunological
response compared to DMRIE-DOPE and therefore repre-
sents a good candidate for formulation of a rabies pDNA
vaccine, and potentially other vaccines that depend pri-
marily on an antibody response for protection. Neutraliz-
ing antibody levels in the pDNA:Vaxfectin™ mice groups
were statistically superior to those observed in the
pDNA:DMRIE-DOPE groups at either 4:1 or 2.5:1 molar
ratios. The difference between Vaxfectin™ and DMRIE-
DOPE was emphasized at the lower dose (2 µg; p = 0.004)
while still being statistically significant at the 5 µg dose (p
= 0.009). Interestingly, the neutralizing antibody titers for
the DMRIE-DOPE groups formulated at the 4:1 molar
Neutralizing Titers after Single Administration of PDNA:DMRIE-DOPE in rabbitsFig e 2
Neutralizing Titers after Single Administration of 
PDNA:DMRIE-DOPE in rabbits. Groups of three rabbits 
were vaccinated with either 300 µg (❍; dotted line) or 10 µg 
(∆; dashed line) of rabies G protein pDNA VR7203 as 
described in Materials and Methods. pDNA:cationic lipid 
molar ratio was kept at 4:1. Control group was vaccinated 
with IMRAB® 3(● ; solid line). Lines connect mean titer val-
ues for each group at each time point. Protection threshold 
(0.5 IU/mL) is indicated with a horizontal line.Page 4 of 6
(page number not for citation purposes)
Genetic Vaccines and Therapy 2006, 4:2 http://www.gvt-journal.com/content/4/1/2ratio were consistently higher than for the 2.5:1 molar
ratio groups. Again, the difference between the DMRIE-
DOPE groups was accentuated at the lower pDNA dose.
The difference between the GMTs (Geometric Mean Titer)
of the two DMRIE-DOPE ratios used is statistically mar-
ginal and will require further investigation. It is important
to note that we present neutralizing antibody titers for one
time point only (48 days after vaccination) since relative
differences in GMT could change over time. However, our
data indicate that formulation of pDNA with Vaxfectin™
elicits fast and robust humoral responses to rabies G pro-
tein. In addition, all mice in the Vaxfectin™ groups had
antibody levels well above the protective threshold (0.5
IU/mL) while there were non-responder animals in the
DMRIE-DOPE groups at the low dose (2 µg).
Rabbit immunogenicity data presented here confirm that
high persistent neutralizing titers can be obtained with
low pDNA doses. In fact, a single dose of 10 µg of DMRIE-
DOPE-formulated pDNA elicited neutralizing titers
almost two orders of magnitude over the protective
threshold (0.5 IU/mL) that persisted for at least 120 days
after administration. The magnitude and duration of the
response were equivalent to that obtained with a single
administration of a traditional rabies veterinary vaccine.
The upper limit of the humoral response to DMRIE-
DOPE-formulated pDNA in the rabbit was determined by
administering three 1 mg doses. The antibody titers
obtained after this vaccination regimen reached 100 IU/
mL by day 41 and did not increase after the day 56 booster
injection. High titers were maintained for the duration of
the study (195 days). The magnitude of this response was
statistically equivalent to that obtained after a single injec-
tion of 300 µg of the cationic lipid-formulated pDNA vac-
cine. The kinetics of the response after a single
administration of 10 µg of pDNA were slower than those
observed after administration of 300 µg of the vaccine.
Titers at day 21 were about one order of magnitude lower
for the 10 µg dose group compared to the 300 µg group.
However, titers were statistically equivalent by day 91 and
stayed comparable for the duration of the study. This lat-
ter observation suggests that the dose-dependent kinetics
of the response need to be considered when designing a
vaccine for post-exposure applications, as lower doses
could be used for vaccines intended for pre-exposure
prophylaxis.
In conclusion, our data suggest that the choice of cationic
lipid and the optimization of pDNA:cationic lipid ratios
can offer significant enhancement of the humoral
response to rabies G protein and potentially other anti-
gens. Specifically, the use of Vaxfectin™ in a rabies pDNA
formulation may increase effectiveness while allowing for
delivery of low doses of pDNA. The results of this research
provide valuable information for development of a rabies
pDNA vaccine for the developing world.
Abbreviations
bp, base pairs; GMT, Geometric Mean Titer; IU, Interna-
tional Unit; PBS, phosphate buffered saline; pDNA, plas-
mid DNA
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